Kinase Inhibitors and Ovarian Cancer

Cancers

Jayanta Chatterjee¹  Juhi Kumar²  Emmanouil Karteris²  Manreen Pandhal²  Dimple Chudasama²  Louise Sales²  Periklis Katopodis²  Gurleen Wander³  Vladimir Anikin⁴  Marcia Hall⁵ 

[1] Harefield NHS Foundation Trust, Harefield Hospital, London UB9 6JH, UK;Biosciences, College of Health and Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK;Chelsea and Westminster Hospital NHS Trust, London UB9 6JH, UK;;Division of Thoracic Surgery, The Royal Brompton &Faculty of Health and Medical Sciences, School of Biosciences and Medicine, University of Surrey, Guildford GU2 7XH, UK;

关键词: kinase inhibitors;    rapalogs;    ovarian cancer;    mTOR;    TKI;   

DOI  :  10.3390/cancers11091357

来源: DOAJ

【 摘 要 】

Ovarian cancer is fifth in the rankings of cancer deaths among women, and accounts for more deaths than any other gynecological malignancy. Despite some improvement in overall-(OS) and progression-free survival (PFS) following surgery and first-line chemotherapy, there is a need for development of novel and more effective therapeutic strategies. In this mini review, we provide a summary of the current landscape of the clinical use of tyrosine kinase inhibitors (TKIs) and mechanistic target of rapamycin (mTOR) inhibitors in ovarian cancer. Emerging data from phase I and II trials reveals that a combinatorial treatment that includes TKIs and chemotherapy agents seems promising in terms of PFS despite some adverse effects recorded; whereas the use of mTOR inhibitors seems less effective. There is a need for further research into the inhibition of multiple signaling pathways in ovarian cancer and progression to phase III trials for drugs that seem most promising.

【 授权许可】

Unknown